Nano-X Imaging Ltd. Stock Price, News & Analysis

Nano-X Imaging Ltd (NASDAQ: NNOX) reported a revenue increase to $2.2 million for Q2 2022, up from $1.8 million in Q1 2022. Cash, cash equivalents, and marketable securities totaled $126.7 million as of June 30, 2022. Key developments include plans for deploying the Nanox.ARC in Nigeria and a partnership with BIO Ventures for Global Health. The company faced a net loss of $19.6 million, compared to $13.6 million in Q2 2021, largely due to increased R&D and general administrative expenses. The gross loss was $1.8 million during the quarter.

Nano-X Imaging Ltd (NASDAQ: NNOX) will announce its Q2 financial results ending June 30, 2022, on August 16, 2022, before market opening. CEO Erez Meltzer and CFO Ran Daniel will host a conference call at 8:30 a.m. ET for a business update. The company aims to enhance accessibility to medical imaging through its technology, which includes the Nanox System and Nanox.CLOUD. Forward-looking statements carry risks related to technology development and market acceptance, underscoring the uncertainties surrounding the company's future performance.

NANO-X IMAGING LTD (NASDAQ: NNOX) reported its first-quarter 2022 results, achieving $1.8 million in revenue, a notable increase from $0 in Q1 2021. This reflects a 38% growth compared to $1.3 million in Q4 2021. The company reported a net loss of $21.7 million, up from $12.7 million in the prior year, driven by increased R&D and administrative expenses. As of March 31, 2022, cash and marketable securities stood at $139.5 million. The company continues to make strides in securing regulatory approvals and expanding its customer base.

Nano-X Imaging Ltd (NASDAQ: NNOX) will release its Q1 2022 results on May 19, 2022, before market opening. CEO Erez Meltzer and CFO Ran Daniel will host a conference call at 8:30 a.m. ET to discuss the results and business updates. Interested parties can join via phone or access the webcast through provided links. Nano-X is committed to enhancing diagnostic imaging accessibility and affordability globally, utilizing advanced technology like the Nanox.ARC and Nanox.CLOUD.

NANO-X IMAGING LTD (Nasdaq: NNOX) has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021, with the U.S. SEC on May 2, 2022. This report includes the company's audited consolidated financial statements, which can be accessed on the SEC's and Nanox's websites. Nanox aims to enhance diagnostic medicine accessibility and affordability through its proprietary imaging technology and solutions. Shareholders can request a hard copy of the annual report free of charge by contacting Investor Relations.

NANO-X IMAGING LTD (NASDAQ: NNOX) announced FDA 510(k) clearance for its HealthOST device, an AI software for detailed spinal analysis, particularly in diagnosing vertebral compression fractures and low bone density. This is the tenth FDA clearance for Nanox.AI, enhancing its portfolio aimed at improving musculoskeletal disease detection. HealthOST aims to support clinicians and potentially prevent serious conditions like osteoporosis, affecting over 10 million in the U.S. The device offers precise measurements and automated identification of critical findings.

NANO-X IMAGING LTD (NNOX) has opened a new operational semiconductor chip fabrication plant in Yongin, South Korea. This facility will produce the Nanox.SOURCE chip, critical for the Nanox.ARC system, aiming to democratize access to X-ray technology globally. Covering 12,000 square meters, it is located near a semiconductor cluster, boosting manufacturing capabilities. The company plans to ramp up production by mid-2022, enhancing its vertical integration strategy amidst global supply chain challenges. This facility signifies a pivotal step in providing affordable medical imaging solutions.

NANO-X IMAGING LTD (NASDAQ: NNOX) announced its fourth quarter results for 2021, reporting a revenue of $1.3 million compared to $0 for the same period in 2020. The non-GAAP gross profit stood at $0.2 million. The company strengthened its leadership and completed its technology transfer to Nanox Korea. However, a net loss of $22 million was reported, an increase from $19 million in Q4 2020, driven by merger-related expenses. Cash and equivalents decreased to $88.7 million, down from $213.5 million year-over-year.

Nano-X Imaging Ltd (NASDAQ: NNOX) will announce its fourth quarter and full year results for 2021 on March 31, 2022, before the market opens. CEO Erez Meltzer and CFO Ran Daniel will lead a conference call at 8:30 a.m. ET to discuss the financial results and business updates. Interested parties can join the call by dialing specific numbers or via a webcast link, which will also be available on the Investor Relations section of the Nanox website. The company aims to innovate affordable digital X-ray technology for global medical imaging.